The human and economic burden associated with healthcare in Europe is overwhelming, accounting for more than 10% of Europe’s GDP (1.5 thousand billion euro, equivalent to more than the combined wealth of 177 countries worldwide) and this is projected to increase to 14% by 2050 unless costs are contained. There are three main challenges with existing models of healthcare:

  • There is a lack of understanding of the aetiologies and underlying mechanisms of many diseases (such as comorbidities and sex-related differences) across the development and progress of the disease.
  • A large number of patients do not respond to available treatment.
  • The current model of care is predicated on treatment rather than prevention.

Personalised Medicine (PM) brings the promise of revolutionising medicine with a potential impact for the healthcare system similar to the antibiotics revolution in 20th century. The later involves tailoring medicine to a person’s unique conditions and is developed by integrating a person’s genetic blueprint with data about their lifestyle and environment, then comparing it alongside thousands of others to predict illness and determine the best treatment. Pharmacogenomics, the study of variations of DNA and RNA characteristics as related to drug response, is one of the most exciting areas of personalised medicine today. The field arises from the convergence of advances in pharmacology (the science of drugs) and genomics (the study of genes and their functions). Patients typically have variable response to different drugs that are currently available. It can be difficult to predict who will benefit from a medication, who will not respond at all, and who will experience adverse effects. Pharmacogenomics seeks to understand how differences in genes and their expression affect the body’s response to medications.

ahedd’s expertise and technical innovation can be traced through the large number of related initiatives, such as the iASis, BigMedilytics and BioAsq Horizon projects and the Hellenic Network for Precision Medicine.

What is more, founding members of the Hub organise events for precision medicine, like the Precision Medicine Symposium.

Relevant Market Sectors

  • Hospitals/Clinicians
  • Health public policies bodies

Actions & Services

  • Machine learning and NLP techniques for analysing large heterogeneous health data and turn them into actionable knowledge
  • Big Data Management
  • EHR analysis

Business Partners

  • Hellenic BioCluster (HBio) is the first biosciences cluster in Greece bringing together the innovation leaders of Greece in the sectors of Pharmaceuticals, Biotechnology, Diagnostics, Medical Devices and Specialist Services.
  • Biovista is a drug repositioning company established in 1993 with offices in Charlottesville VA, USA and Athens, Greece. Biovista’s repositioning programs leverage the company’s technology platform to identify suitable drugs and reposition them in isolation or in combination with other drugs to therapeutic areas that are currently not covered by existing products.